Biopharmaceutical Midday Gainers: QGLY, BPAX, NXXI - sourced

The Quigley Corporation, Biosante Pharmaceuticals, Inc, Nutrition 21, Inc

Calgary, AB 8/18/2009 12:25 AM GMT (TransWorldNews)

Calgary, Alberta - opines promising trading opportunities with likely potential for gain. The companies we follow have favourable revenue models for business development at upward cycles.  To view more of our profiled stocks, please visit us at


Biopharmaceutical Midday Gainers: QGLY, BPAX, NXXI


The hot stock information of the day includes:


The Quigley Corporation (NASDAQ:QGLY) skyrocketed 79.18% up to $3.05 on no news.  The company posted Q2 losses last week, due chiefly to legal fees related to “the proxy contest between differing slates of proposed boards of directors”; however the company asserts its devotion to methodical strategies and the development and commercializing of new OTC products.   The company’s subsidiary Quigley Pharma announced positive results a couple of weeks ago from their double blind study of symptomatic diabetic peripheral neuropathy. Based in Doylestown, Pennsylvania, The Quigley Corporation is diversified natural health medical science company distributing homeopathic and health products in the US. It offers over the counter cold remedy products, including Cold-Eeze, a zinc gluconate glycine product for the common cold.  The company also provides prescription medicines along with supplements and cosmeceuticals for human and veterinary use. It distributes its products through food, chain drug, and mass merchandisers.


Biosante Pharmaceuticals, Inc. (NGM: BPAX) maintained its gain of 15.82% by midday to rise to $2.27 (the company was up 25%  in pre-trading) on news clinical trials show that it’s booster adjuvant bio-enhances and increases the efficacy of vaccines, including new vaccines for H1N1.  Based in Lincolnshire, Illinois, Biosante Pharmaceuticals is a biopharmaceutical company developing hormone therapy products to treat men and women.  It also develops proprietary nanotechnology. The company also produces aesthetic derma filers, BioVant for the treatment of viral and bacterial infections and autoimmune diseases, as well as inhalable applications for protein and therapy administration.


Nutrition 21, Inc. (NASDAQ:NXXI) rose 9.92% up to $0.154 on no official news.   The company is due to announce quarter financial results on the next weeks as it seeks to renegotiate extensions or restructuring of banknotes secured by the Iceland Health(R) trademark.  Headquartered in Purchase, New York, Nutrition 21, Inc. is a nutritional bioscience company, develops, markets, and distributes clinically substantiated nutritional supplements in the US,and and holds more than 30 patents for nutrition products




To be kept up to date on all of our hot stock information join us at Picks That Move.


About is an independent electronic publication that provides information on selected publicly traded companies. is not a registered investment advisor or broker-dealer. affiliates, officers, directors and employees may buy and sell shares in any company mentioned herein and may profit in the event those shares rise in value.  We recommend Due Diligence before investing in any stock.





News Alerts

Receive alerts for QGLY to your inbox. Sign up for News Alerts